Share This Article
Outsourcing cell culture and cell banking is an increasingly common strategy among drug discovery teams looking to boost efficiency, reduce costs, and mitigate risk. But is it right for your program?
Here are key factors to consider:
- Do you need to scale quickly or conserve internal resources?
Maintaining in-house capabilities for cell expansion, media optimization, and master cell bank (MCB) production requires significant investment in equipment, facilities, and experienced staff. Outsourcing lets you tap into ready-built infrastructure and expertise—ideal for teams focused on early discovery and needing to move fast. - Is rigorous quality assurance essential?
Authenticating cell lines, testing for mycoplasma, sterility, and viral contamination demands specialized staff and facilities. If these QC measures are critical to your program, partnering with an organization that treats quality as a core competency can save time and reduce risk. - Do your cells require specialized expertise?
Handling and growing critical cell lines demands deep technical knowledge to ensure reliability and reproducibility. If your cells are essential to key research programs, outsourcing to dedicated professionals can help safeguard quality and consistency. - How variable or complex are your cell lines?
Primary cells, engineered lines, or rare cell types may require custom culture conditions and monitoring. Outsourcing to a provider with deep technical expertise can improve consistency and success rates—especially when working with fragile or non-standard cells. - Do you need secure, reliable access to cells on demand?
Beyond high-quality production, long-term storage and easy retrieval are key. The right partner offers validated storage, precise inventory tracking, and flexible delivery options so you can focus on research while knowing your cells are safe and accessible when needed.
Bottom Line:
If your team wants to stay focused on discovery science without taking on the operational and regulatory burdens of cell culture and banking, outsourcing may be a smart move. The right partner can ensure reliability, quality, and speed—allowing your scientists to do what they do best: innovate.

HARMINDER SINGH, M.D.
Business Development Director, ABS Bio
15+ years in life sciences
Biospecimen operations expert
Precision medicine research
Harminder Singh, M.D. is Business Development Director at ABS Bio. He joined ABS Bio from Cureline, where he was instrumental in leading biospecimen operations. He brings more than 15 years of experience in the life sciences industry and is a recognized expert in human biospecimen sourcing, management, and global clinical research. Dr. Singh is actively engaged in designing and executing research projects involving human biospecimens to help develop precision medicine therapies. He has a strong track record of building and maintaining long-term partnerships with clinical networks and pharmaceutical/biotechnology clients.